- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02316444
Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda
Strategies for the Prevention of Hepatitis B Viral Infection Among HIV Infected Adults in Uganda
The aim of this study is to compare the effectiveness of two vaccination strategies against Hepatitis B virus (HBV) in subjects already infected with human immunodeficiency virus (HIV).
Researchers plan to determine the optimal vaccination strategy for achieving protective immunity to HBV infection in HIV-infected adults attending Mulago Hospital's HIV care clinic.
Primary objectives are to assess:
- The role of CD4-cell count and HIV viral loads on the HBV vaccine response.
- The role of highly active antiretroviral therapy (HAART) on the HBV vaccine response.
The secondary objective is to evaluate whether lack of HAART is associated with high rates of loss to follow-up.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is an interventional study in which researchers will recruit HIV positive individuals who do not have hepatitis B (HBV negative) in order to assess the effectiveness of a hepatitis B vaccine in 2 subgroups:
- Those who have received less than 3 months treatment, or no treatment, with highly active antiretroviral drugs (HAART naive).
- Those who have received at least 3 months of treatment with highly active antiretroviral drugs (HAART exposed).
All study participants will receive vaccination against HBV.
There will be 6-12 clinic visits depending on 1) whether or not the participant responds to the standard 3-dose vaccination protocol and 2) whether he or she suffers a clinical condition or vaccine related adverse event that would call for postponement of the next vaccine dose.
The first visit will be to determine if the participant is eligible for the study. If eligible, the participant will receive one dose of vaccine at each of the following three visits. The fifth visit will be to collect blood to determine whether the participant has responded to the 3-dose vaccination protocol. The sixth visit will be to discuss the outcome of the vaccination with the participant. Participants who respond favorably to the 3-dose vaccine protocol will exit the study at this point. However, if a participant fails to respond to the initial 3-dose vaccine protocol, he or she may restart the regimen and receive another 3 doses of vaccine following the same schedule as before but off protocol.
Participants will be reimbursed for travel costs to and from the clinic for scheduled clinic visits.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
Kampala, Uganda
- Mulago National Referral Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Hepatitis B core antibody (anti-HBc) and anti-HBs negative
- Age ≥18 years
- HIV infected persons (HAART naïve and HAART exposed). HAART enrollees will be considered to be HAART exposed if they have been taking these medications for at least 3 months. Participants that have never been on HAART and those that have been on HAART for <3months will be considered to be HAART naïve. HAART exposed enrollees will have an adherence of at least 95%.
- Ambulatory
- Intention to attend the Mulago HIV/AIDS clinic for the 18 months
- Able and willing to comply with study protocol including providing informed consent
Exclusion Criteria:
- History of hypersensitivity to vaccines or intolerance to any of the HBV vaccine components
- Previously-confirmed diagnosis of decompensated liver disease or HCC
- Serological evidence of prior receipt of the HBV vaccine (anti-HBS positive, anti-HBc negative) or documented (clinical) evidence of having been vaccinated.
- Known history of HBV infection (HBsAg and/or anti-HBc positive).
- Inability to follow study procedures
- If a participant chooses not to consent to the review of his or her medical records
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Altro: HAART exposed
Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
|
An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular).
Then their immune response will be assessed.
Non responders will receive 3 additional vaccine doses off protocol
Altri nomi:
|
Altro: HAART naive
Participants in both arms will receive the Hepatitis B vaccine as summarized in the study description
|
An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular).
Then their immune response will be assessed.
Non responders will receive 3 additional vaccine doses off protocol
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Hepatitis B virus (HBV) vaccine response
Lasso di tempo: 18 months
|
Measure Hepatitis B surface antibody (anti-HBs) levels and cell mediated immune response.
|
18 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Loss to follow-up (HAART naive vs. HAART exposed individuals)
Lasso di tempo: 18 months
|
Compare the number of individuals lost to follow-up among the HAART naive and HAART exposed.
|
18 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Ponsiano Ocama, PhD, Makerere University
- Investigatore principale: Corey Casper, MD, Fred Hutchinson Cancer Center
- Investigatore principale: Emmanuel Seremba, MMED, HCRI-Ug, Makerere University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- U010
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su HIV/AIDS e infezioni
-
University of MinnesotaRitiratoInfezioni da HIV | HIV/AIDS | HIV | AIDS | Problema di Aids/Hiv | AIDS e infezioniStati Uniti
-
University of California, San DiegoNational Institute of Allergy and Infectious Diseases (NIAID)Completato
-
University of Massachusetts, BostonCompletato
-
Stanford UniversityJanssen Services, LLCCompletato
-
ViiV HealthcareJohns Hopkins University; Pfizer; Vanderbilt University; University of North Carolina...Completato
-
Medical College of WisconsinCompletato
-
Emory UniversityCompletato
-
Rhode Island HospitalSconosciutoHIV | AIDSStati Uniti
-
Tibotec Pharmaceuticals, IrelandCompletato
-
Lampiris, Harry W., M.D.AbbottSconosciuto
Prove cliniche su Hepatitis B vaccine
-
TASK Applied ScienceCompletatoCOVID-19 | SARS-CoV-2Sud Africa
-
National Institute of Allergy and Infectious Diseases...Dynavax Technologies CorporationAttivo, non reclutanteInfezione da HIV | Epatite BStati Uniti, Haiti, Botswana, Filippine, Tailandia, Brasile, Kenya, Malawi, Sud Africa, Uganda, Vietnam
-
BioNTech SECompletatoCOVID-19 | Infezione da SARS-CoV2 | Malattia respiratoria acuta SARS-CoV-2 | SARS (malattia)Stati Uniti, Germania, Tacchino, Sud Africa
-
ChemoCentryxMedpace, Inc.CompletatoGlomerulosclerosi focale segmentale | FSGS | GlomerulosclerosiStati Uniti, Francia, Italia, Australia, Regno Unito, Canada, Nuova Zelanda, Polonia
-
Indiana UniversityAlcon ResearchCompletato
-
Marya Strand, MDCompletatoSindrome da stress respiratorioStati Uniti
-
Wright State UniversityReclutamentoCancro della pelleStati Uniti
-
Epstein, Arthur B., OD, FAAOAlcon ResearchCompletato
-
Eli Lilly and CompanyCompletato
-
Coopervision, Inc.COREAttivo, non reclutante